Patient in ACTC Stem Cell Clinical Trial With Dry AMD Goes from Legally Blind (20/400) to Near Normal Vision (20/40)
May 20, 2013
As you may know, Advanced Cell Technology is currently running three stem cell clinical trials; two for treating Stargardt’s Disease, one in the U.S. and one in the UK; and one clinical trial in the U.S. for treating the dry form of AMD.
Due to a unique set of circumstances, it was disclosed that one of the dry AMD patients has gone from 20/400 (legally blind) to 20/40 (near normal vision). This is an amazing development.
Here is the story behind the story of how this disclosure occurred.
To read the story, please follow this link.
Here is a link to the company’s press release concerning the development.
Jump down to form below to submit your own comments